Lydd, our manufacturing strategy is built on partnerships with WHO-GMP and ISO-certified pharmaceutical plants across India.

We operate under a third-party manufacturing model, allowing us to combine flexibility, scalability, and strict quality assurance without heavy infrastructure investment.

 

Our product range includes:

 

• Generic formulations (tablets, capsules, syrups, injectables)

• Nutraceuticals and wellness products

• Antibiotics, analgesics, antihypertensives, and anti-diabetic ranges

• Specialty and branded generics for export markets

 

 

Manufacturing Capabilities

 

• Facilities approved by WHO-GMP / Schedule-M and compliant with international regulatory standards

• Dedicated lines for oral solids, liquids, and injectables

• Batch traceability with digital QC documentation and barcode tracking

• Validated processes for stability, sterility, and bioavailability

• Strict adherence to Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP)

 

 

Quality Control & Compliance

Every batch is tested in state-of-the-art QC labs, ensuring conformity with Indian Pharmacopoeia (IP), British Pharmacopoeia (BP), and United States Pharmacopoeia (USP) standards.

Our QA team conducts end-to-end inspections, from raw material sourcing to final packaging, to maintain export-grade quality and shelf stability during transit.

 

Export Orientation

Our formulations are manufactured in compliance with the regulatory requirements of African and emerging markets. We maintain close collaboration with local distributors, registration agents, and health ministries to ensure smooth market entry.

Each shipment is supported by full technical documentation — COA, COPP, stability data, and CTD dossiers for product registration.

 

Why Our Manufacturing Model Works

 

• Asset-light, partner-driven scalability

• Multi-product flexibility with short lead times

• Lower production cost and faster export readiness

• Sustainable quality systems aligned with global norms